中高危前列腺癌:放疗联合ADT与根治性前列腺切除术的成本效果比较
本研究采用马尔可夫模型进行成本效果分析,比较中高危前列腺癌患者接受放疗联合雄激素剥夺治疗(ADT)与根治性前列腺切除术(RP)后必要时辅助放疗的质量调整生命 expectancy(QALE)和成本。结果显示,在所有分析和广泛假设下,RT+ADT均为首选策略,QALE较RP提高0.5至1.14质量调整生命年,且在所有情境下均具成本效果(低于每QALY 10万美元阈值)。RP组发生单一或多重治疗毒性的比例更高。
要点
- RT+ADT在中高危前列腺癌中QALE优于RP,提高0.5–1.14 QALY。
- RT+ADT在所有情境下均低于每QALY 10万美元的成本效果阈值。
- RP组发生单一或多重治疗毒性的患者比例更高。
核心结论
- 对于中高危前列腺癌,放疗联合ADT可能较根治性前列腺切除术改善质量调整生命 expectancy。
- 尽管两组生化失败率相似,但 upfront RP 患者发生多重毒性的比例更高。
研究设计与样本
- 研究采用马尔可夫模型进行成本效果分析,允许患者按年度概率在健康状态间转移,概率按 favourable intermediate、unfavourable intermediate 或 high-risk 前列腺癌分组赋值。
- 主分析针对65岁患者,次要分析探索年轻年龄、基线心血管风险升高及挽救治疗的影响,并进行了单因素和概率敏感性分析。
主要发现
- 在所有主分析和次要分析中,采用广泛假设范围,RT+ADT均为中高危前列腺癌男性的首选治疗策略。
- RT+ADT后的QALE较RP提高0.5至1.14质量调整生命年。
- RT+ADT在所有情境下均具成本效果,低于每质量调整生命年10万美元的阈值。
- 在所有风险组中,接受RP的患者发生单一或多重治疗毒性的比例更高。
关键数值与推荐
- RT+ADT的QALE较RP提高0.5至1.14 QALY。
- RT+ADT在所有情境下低于每QALY 100,000美元的成本效果阈值。
临床怎么用
- 在中高危前列腺癌治疗决策中,可考虑将RT+ADT作为兼具生存质量与成本效果优势的首选策略。
- 需向患者说明RP后发生单一或多重治疗毒性的比例更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare, using a cost-effectiveness analysis, the quality-adjusted life expectancy (QALE) and cost between the 2 treatment options for intermediate- to high-risk prostate cancer: (1) radiation (RT) with androgen deprivation therapy (ADT) or (2) radical prostatectomy (RP) followed by adjuvant RT for patients with risk factors. METHODS AND MATERIALS: Our Markov model allowed patients to transition between health states with yearly probabilities of developing cancer recurrence and/or toxicity. Probabilities were assigned according to favorable intermediate, unfavorable intermediate, or high-risk prostate cancer groups. The primary analysis examined outcomes for patients aged 65 years, whereas secondary analyses explored the effects of younger age, elevated baseline cardiovascular risk, and the use of salvage therapy. One-way and probabilistic sensitivity analyses were performed. RESULTS: Across all primary and secondary analyses, and using a wide-range of assumptions, RT + ADT was the preferred treatment strategy for men with intermediate- to high-risk prostate cancer. The QALE was higher after RT + ADT by 0.5 to 1.14 quality-adjusted life years, compared with RP. Radiation plus ADT was cost-effective in all situations, falling beneath a threshold of $100,000 per quality-adjusted life year. Among all risk groups, a greater proportion of patients undergoing RP experienced single or multiple treatment toxicities. CONCLUSIONS: Radiation plus ADT may result in improved QALE compared with RP for intermediate- to high-risk prostate cancer. Although biochemical failure is similar between treatment groups, there is a higher rate of developing multiple toxicities among patients treated with upfront RP.
引用
- Dorth JA, Lee WR, Chino J, et al. Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29353655. doi:10.1016/j.ijrobp.2017.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。